Many companies make a serious mistake in not assessing the regulatory status of a company targeted for M&A. Many times, the compliance problems associated with the target represent substantial expense for corrective action. DBT assesses M&A targets from the perspective of:
- Reviewing the regulatory and compliance history of the target
- Assessing their responses to FDA
- Determining 510k status of key products
Please contact us about a customizing an assessment for your project.